Rep. Robert Bresnahan, Jr. Purchases Shares of Waters Co. (NYSE:WAT)

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of Waters Co. (NYSE:WAT). In a filing disclosed on March 27th, the Representative disclosed that they had bought between $1,001 and $15,000 in Waters stock on February 25th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 3/7/2025.
• Sold $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 3/6/2025.
• Purchased $1,001 – $15,000 in shares of SEA (NYSE:SE) on 3/5/2025.
• Sold $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Twilio (NYSE:TWLO) on 3/4/2025.
• Sold $15,001 – $50,000 in shares of Alibaba Group (NYSE:BABA) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Zoom Video Communications (NASDAQ:ZM) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Intel (NASDAQ:INTC) on 3/3/2025.
• Purchased $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 3/3/2025.

Waters Price Performance

NYSE WAT traded down $8.98 during midday trading on Friday, hitting $361.61. The company had a trading volume of 277,709 shares, compared to its average volume of 454,529. The company has a market capitalization of $21.48 billion, a PE ratio of 33.76, a P/E/G ratio of 3.79 and a beta of 1.00. Waters Co. has a twelve month low of $279.24 and a twelve month high of $423.56. The company has a current ratio of 0.94, a quick ratio of 0.65 and a debt-to-equity ratio of 1.14. The firm has a 50-day moving average price of $387.41 and a 200-day moving average price of $372.60.

Waters (NYSE:WAT) last announced its quarterly earnings results on Wednesday, February 12th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.02 by $0.08. Waters had a net margin of 21.56% and a return on equity of 46.31%. As a group, analysts anticipate that Waters Co. will post 12.86 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on WAT shares. Baird R W upgraded shares of Waters from a “hold” rating to a “strong-buy” rating in a research note on Wednesday. StockNews.com lowered Waters from a “buy” rating to a “hold” rating in a research report on Tuesday, February 25th. UBS Group lifted their price target on shares of Waters from $405.00 to $410.00 and gave the company a “neutral” rating in a report on Thursday, February 13th. Sanford C. Bernstein upgraded shares of Waters from a “market perform” rating to an “outperform” rating and set a $430.00 price target for the company in a research note on Friday, January 10th. Finally, Barclays raised Waters from an “underweight” rating to an “equal weight” rating and upped their price objective for the company from $360.00 to $415.00 in a research report on Monday, February 10th. Ten equities research analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Waters currently has an average rating of “Moderate Buy” and an average target price of $397.40.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in WAT. Wealthfront Advisers LLC grew its position in Waters by 106,144.4% during the 4th quarter. Wealthfront Advisers LLC now owns 3,087,461 shares of the medical instruments supplier’s stock worth $1,145,386,000 after acquiring an additional 3,084,555 shares during the last quarter. Norges Bank bought a new position in Waters during the 4th quarter worth $284,415,000. Millennium Management LLC increased its stake in Waters by 3,349.7% during the 4th quarter. Millennium Management LLC now owns 304,404 shares of the medical instruments supplier’s stock worth $112,928,000 after acquiring an additional 295,580 shares during the period. Madison Investment Advisors LLC acquired a new stake in Waters in the fourth quarter valued at about $104,645,000. Finally, Principal Financial Group Inc. increased its stake in shares of Waters by 70.7% in the third quarter. Principal Financial Group Inc. now owns 656,019 shares of the medical instruments supplier’s stock valued at $236,095,000 after buying an additional 271,804 shares during the period. 94.01% of the stock is currently owned by institutional investors and hedge funds.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.

Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

Waters Company Profile

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.